3,120,394 Shares in Boston Scientific Corporation $BSX Acquired by Caisse de depot et placement du Quebec

Caisse de depot et placement du Quebec bought a new stake in shares of Boston Scientific Corporation (NYSE:BSX) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 3,120,394 shares of the medical equipment provider’s stock, valued at approximately $133,178,000.

Other large investors have also recently added to or reduced their stakes in the company. Kelleher Financial Advisors bought a new position in shares of Boston Scientific in the second quarter valued at $25,000. FWL Investment Management LLC bought a new stake in shares of Boston Scientific during the 2nd quarter worth $26,000. Swiss RE Ltd. bought a new stake in shares of Boston Scientific during the 4th quarter worth $26,000. Garton & Associates Financial Advisors LLC acquired a new position in shares of Boston Scientific in the 4th quarter worth $26,000. Finally, Clal Insurance Enterprises Holdings Ltd acquired a new position in shares of Boston Scientific in the 1st quarter worth $28,000. 89.07% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently commented on BSX. Daiwa Securities Group downgraded Boston Scientific from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. Mizuho dropped their price target on Boston Scientific from $90.00 to $70.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 15th. Canaccord Genuity Group cut their price objective on Boston Scientific from $70.00 to $66.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. The Goldman Sachs Group set a $71.00 price objective on shares of Boston Scientific in a research note on Thursday, May 28th. Finally, Wall Street Zen cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Sunday, August 2nd. Twenty-four investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $71.62.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Negative Sentiment: Cyberattack disrupted operations: Boston Scientific said the incident, identified Tuesday, affected information systems used to process customer orders and ship products worldwide. Some systems remain inaccessible, and the company has not provided a firm timeline for full restoration, increasing uncertainty over near-term sales. Reuters report on Boston Scientific cyberattack
• Negative Sentiment: Shipment delays could weigh on results: The disruption is limiting order processing and product deliveries. Investors are concerned that prolonged delays could defer revenue, raise remediation expenses and potentially affect the company’s earnings outlook. CNBC report on Boston Scientific cyberattack
• Negative Sentiment: Additional product-recall concerns: Coverage also highlighted a cardiac-device recall, adding another operational and reputational risk for the medical-device maker at a time when investors are already focused on execution and potential liability. Seeking Alpha report on cardiac device recall
• Neutral Sentiment: Fundamentals provide some support: Boston Scientific recently reported quarterly revenue growth and earnings above analyst expectations, but the cyber incident creates uncertainty about whether that operating momentum can continue in the near term. The Motley Fool coverage of Boston Scientific

Insider Buying and Selling at Boston Scientific

In other news, Director David C. Habiger acquired 2,100 shares of the business’s stock in a transaction that occurred on Wednesday, August 5th. The stock was acquired at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the acquisition, the director owned 17,160 shares in the company, valued at approximately $816,644.40. The trade was a 13.94% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Edward J. Ludwig acquired 5,000 shares of Boston Scientific stock in a transaction that occurred on Friday, July 31st. The shares were purchased at an average cost of $45.48 per share, with a total value of $227,400.00. Following the transaction, the director owned 30,359 shares of the company’s stock, valued at approximately $1,380,727.32. The trade was a 19.72% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased 194,522 shares of company stock valued at $9,385,210 in the last quarter. Company insiders own 0.34% of the company’s stock.

Boston Scientific Price Performance

Shares of BSX opened at $48.22 on Thursday. The business’s 50-day moving average is $46.51 and its 200-day moving average is $56.93. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. The company has a market capitalization of $69.88 billion, a price-to-earnings ratio of 19.52, a P/E/G ratio of 1.09 and a beta of 0.56. Boston Scientific Corporation has a fifty-two week low of $42.20 and a fifty-two week high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping the consensus estimate of $0.83 by $0.03. The business had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same period last year, the company posted $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities research analysts expect that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific announced that its Board of Directors has initiated a stock buyback plan on Monday, May 18th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s board of directors believes its shares are undervalued.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.